arrow_back Back to App

Boosting Pediatric Cancer Drug Research, Organ Transplant Efficiency, and Generic Drug Access.

This Act mandates pharmaceutical companies to study new adult cancer drugs for pediatric use if the drug targets relevant molecular pathways, aiming to increase treatment options for children with cancer. It also significantly reforms the organ transplantation system (OPTN) by promoting digitalization and transparency. Furthermore, the law facilitates the market entry of cheaper generic drugs and allocates additional funds to the Medicare Improvement Fund.
Key points
Faster Pediatric Cancer Treatments: Drug companies must investigate new targeted cancer drugs for potential use in children, speeding up access to specialized therapies.
Organ Transplant Transparency: The organ transplant network (OPTN) must integrate electronic health records and increase public transparency regarding organ utilization.
article Official text account_balance Process page
Passed House
Citizen Poll
No votes cast
Additional Information
Print number: 119_HR_1262
Sponsor: Rep. McCaul, Michael T. [R-TX-10]
Process start date: 2025-02-12
Lustra uses Artificial Intelligence. Verify details in source documents.
Summarized by: gemini-flash-latest
Source data: api.congress.gov
AI work logs for this document launch

OFFICIAL LEGAL TITLE

Mikaela Naylon Give Kids a Chance Act

FREQUENTLY ASKED QUESTIONS

What is the official ID of this bill?

The official print number for this legislation is 119_HR_1262.

Which chamber initiated this legislation?

This legislation was initiated in the House of Representatives.

When did the legislative process begin?

The process officially started on 2025-02-12.

What are the main provisions?

Key points include:

  • Faster Pediatric Cancer Treatments: Drug companies must investigate new targeted cancer drugs for potential use in children, speeding up access to specialized therapies.
  • Organ Transplant Transparency: The organ transplant network (OPTN) must integrate electronic health records and increase public transparency regarding organ utilization.
What is the specific legal status?

The current status is Passed House.

Where can I read the full text of this legislation?

The full official text is available at: View full text

Who is the primary sponsor?

The primary sponsor is Rep. McCaul, Michael T. [R-TX-10].

What is the latest detailed status?

The latest detailed status is: On motion to suspend the rules and pass the bill, as amended Agreed to by voice vote. (text: CR H4929-4932)

Is this summary verified?

Yes. This content was analyzed by AI and verified by the Lustra Judge System on 2025-12-23.

CATEGORIES

Health Benefits Economy